EGFR-positive lung cancer is a type of lung cancer that has distinct characteristics and treatment considerations. Resources and support are available for patients with metastatic EGFR-positive non-small cell lung cancer, and the treatment landscape for this condition is evolving. Research and developments in targeted therapies, including tyrosine kinase inhibitors, are ongoing, with emerging treatments showing promise for certain subtypes of EGFR-positive lung cancer.